• Journal of Microbiology and Biotechnology
• /
• 제14권3호
• /
• pp.635-638
• /
• 2004

An ATP-binding-cassette (ABC) transporter gene in the cephabacin biosynthetic gene cluster of Lysobacter lactamgenus was characterized. The amplified orf10 (cpbJ) gene was subcloned into pET-28a(+) vector and expressed in E. coli BL21(DE3) strain by 0.5 mM IPTG at $30^{\circ}C$. The membrane fraction of recombinant E. coli cells was separated by ultracentrifugation, and solubilized using 2.5% octyl-$\beta$-D-glucoside. Using the solubilized membrane fraction, the artificial proteoliposomes were reconstituted and analyzed for the biological activity of CpbJ protein. Upon measuring ATPase activity, the proteoliposome made from recombinant E. coli membrane proteins showed slightly higher activity than that from host E. coli membrane proteins. In the measurement of membrane transport activity, the reconstituted proteoliposome of recombinant E. coli membrane proteins exhibited higher activity when both substrates of cephalosporin C and L-Ala-L-Ser were applied, compared to the case of cephalosporin C or L-Ala-L-Ser only. It implies that the CpbJ protein is an ABC transporter secreting cephabacin antibiotics synthesized in cytoplasm.

• 대한임상독성학회지
• /
• 제4권1호
• /
• pp.65-68
• /
• 2006

Contact urticaria describes a wheal and falre response elicitied within 30-60 minutes after cutaneous exposure to certain agents. Contact urticaria encompasses a number of different clinical manifestations and the symptoms which can vary from the mildest forms of burning, stinging and itching sensation to life-threatening anaphylaxis referred to as contact urticaria syndrome. Cefotiam is one of the most popular second generation cephem antibiotic used in korea. Since 1975, contact urticaria due to cephalosporins has been reported, and also, in japan, this reported from about last 15 years. Recently we experienced three nurses working at the general wards with showing contact urticaria and anaphylaxis after occupational exposure to cefotiam antibiotics.

• 대한화학회지
• /
• 제38권9호
• /
• pp.676-681
• /
• 1994

4-Acetoxyazetidine-2-one과 (3R,4R)-4-acetoxy-3-[(1R)-1-(tert-butyldimethylsilyloxy)ethyl]azetidin-2-one에 2-(tert-butyldimethylsilyloxy)-1,3-butadiene 또는 3-(tert-butyldimethylsilyloxy)-1,3-pentadiene을 염화아연의 존재하에 반응시켰을 때 Diels-Alder 첨가생성물인 cephem 유도체가 얻어졌다. 이 반응에서 diene으로 tert-butyldiemethylsilyl acrylate를 사용하였을 때에는 azetidin-2-one의 4-위치의 acetoxy기가 acryloyloxy로 치환된 화합물이 얻어졌다. 4-phenylsulfonylazetidin-2-one을 dienophile로 사용하여 2-(tert-butyldimethylsilyloxy)-1,3-butadiene과 반응시켰을 때에는 carbacephem은 생성되지 않았고 4-phenylsulfoyl-2-butanone이 얻어졌다. Thiochalcone dimer를 염화아연의 존재하에 4-acetoxyazetidin-2-one과 반응시켰을 때 azetidin-2-one의 고리가 깨어진 화합물이 생성되었고, N-methylacrylamide를 trimethylsilyl trifluoromethanesulfonate와 triethylamine의 존재하에 반응시켜 얻은 2-trimethylsilyloxy-1-aza-1,3-butadiene은 4-acetoxyazetidin-2-one과 Diels-Alder 유형의 반응을 하지 않았다.

• 한국임상약학회지
• /
• 제22권1호
• /
• pp.9-12
• /
• 2012

Background: Cefcapene pivoxil hydrochloride, is an ester-type oral cephem antibiotic. This study was performed to compare the pharmacokinetics and evaluate the bioequivalence of two cefcapene pivoxil hydrochloride 75 mg formulations. Method: In a randomized $2{\times}2$ crossover study, sixty healthy male volunteers were randomly assigned into two groups. After a single dose of 75 mg cefcapene pivoxil hydrochloride oral administration, blood samples were collected at specific time intervals from 0-12 hours. The plasma concentrations of cefcapene pivoxil hydrochloride were determined by LC-MS/MS. The pharmacokinetic parameters were determined from the plasma concentration-time profiles of both formulations. The pharmacokinetic parameters such as $AUC_{last}$, $AUC_{inf}$ and $C_{max}$, were calculated and the 90% confidence intervals for test/reference ratio for pharmacokinetic parameters were obtained by analysis of variance on logarithmically transformed data. Results: The mean value for $AUC_{last}$ in test and reference drug was $4053.1{\pm}876.5\;ng{\cdot}hr/mL$ and $3595.7{\pm}1029.1\;ng{\cdot}h/mL$, respectively. The mean value for $C_{max}$ in test and reference drug was $1324.9{\pm}321.4$ ng/mL and $1159.1{\pm}335.9$ ng/mL, respectively. The 90% confidence intervals of the $AUC_{last}$ and $C_{max}$ ratio for test drug and reference drug were log 1.09-log1.22 and log 1.09-log1.24, respectively. No adverse events were reported by subjects or found on analysis of vital signs or laboratory tests. Conclusion: This single dose study found that the test and reference products met the regulatory criteria for bioequivalence in these health volunteers. Both formulations were safe and well tolerated in 75 mg of cefcapene pivoxil hydrochloride.